A practical reference on eumelanin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-14. Anything still debated is marked as such rather than presented as settled.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Under circumstances in which CENPA is lost from a chromosome a fail-safe mechanism has been described in human cells in which CENPB recruits CENPA via a satellite DNA binding domain to repopulate the centromere with CENPA nucleosomes. CENPA interacts directly with the inner kinetochore through proteins including CENPC and CENPN. Through this interaction the microtubules are able to accurately segregate chromosomes during mitosis.
== Ecology == Dioecy, having separate male and female flowers, has evolved at least three times in the genus, and reversals to a hermaphrodite condition have also occurred, which is a rare occurrence in flowering plants. It has been suggested that dioecy in the genus may correlate with abiotic pollination in the cold environment.
=== Weak base and weak coordinating anion === As perchloric acid is one of the strongest mineral acids, perchlorate is a very weak base in the sense of Brønsted–Lowry acid–base theory. As it is also generally a weakly coordinating anion, perchlorate is commonly used as a background, or supporting, electrolyte.
Sources: en.wikipedia.org
=== 2016: Court of Arbitration for Sport verdict === On 12 January 2016, CAS handed down a guilty verdict on the thirty-four Essendon players, overturning the AFL Anti-Doping Tribunal's not-guilty verdict, after finding it was comfortably satisfied that the players were injected with Thymosin beta-4. Key to the appeal's success was the treatment of evidence: the CAS rejected the AFL Tribunal's approach, known as "links in the chain", where any individual chain of evidence is dismissed if any one link within it cannot be proven, and endorsed WADA's approach, known as "strands in the cable", where individual evidence chains with missing links may still be accepted if the combination of all such chains forms a sufficiently strong case. A complete account of the verdict and the arguments made by each side was released publicly. Vital to the case was determining whether or not the unspecified Thymosin used in the program was the banned Thymosin Beta-4 or a different, legal variety of Thymosin. A paper trail had confirmed that Dank had been dispensed Thymosin Beta-4 by the Como Compounding Pharmacy; however, no direct evidence was found that it was this Thymosin rather than a different legal Thymosin which had been administered to players, and this missing evidence link had been key to the AFL Tribunal's not guilty verdict under the 'links in the chain' method.
Jung proposed that art can be used to alleviate or contain feelings of trauma, fear, or anxiety and also to repair, restore, and heal. In his work with patients and his own personal explorations, Jung wrote that art expression and images found in dreams could help recover from trauma and emotional distress. At times of emotional distress, he often drew, painted, or made objects and constructions, which he recognised as more than recreational. He also encouraged his patients to paint their psychic images.
=== Use === Voluntary use by the public was ineffective. A lack of features and bugs further reduced usefulness. Some apps include "check-ins" that enable exposure notifications when entering public venues such as fitness centres. One such example is the We-Care project that used anonymity and crowdsourced information about which check-ins are essential, to alert exposed users.
Sources: en.wikipedia.org
dolichyl diphosphate + a glycoprotein with the oligosaccharide chain attached by N-glycosyl linkage to protein L-asparagine Thus, the two substrates of this enzyme are dolichyl diphosphooligosaccharide and protein L-asparagine, whereas its 3 products are dolichyl diphosphate, glycoprotein with the oligosaccharide chain attached by N-glycosyl, and linkage to protein L-asparagine. This enzyme belongs to the family of glycosyltransferases, specifically the hexosyltransferases. The systematic name of this enzyme class is dolichyl-diphosphooligosaccharide:protein-L-asparagine oligopolysaccharidotransferase. Other names in common use include dolichyldiphosphooligosaccharide-protein glycosyltransferase, asparagine N-glycosyltransferase, dolichyldiphosphooligosaccharide-protein oligosaccharyltransferase, dolichylpyrophosphodiacetylchitobiose-protein glycosyltransferase, oligomannosyltransferase, oligosaccharide transferase, dolichyldiphosphoryloligosaccharide-protein, and oligosaccharyltransferase. This enzyme participates in n-glycan biosynthesis and glycan structures - biosynthesis 1.
"There's no way Rush will ever exist again because Neil's not here to be a part of it... that's not to say that we can't do other things and we can't do things that benefit our communities and all of that. I have lots of plans for that sort of thing that don't necessarily include Geddy. I get asked this all the time—are we gonna do this, or are we gonna do that? Who knows? All I know is we still love each other and we're still very, very good friends, and we always will be."
=== Into Germany === After helping to secure the Ruhr, the 82nd Airborne Division took over Ludwigslust past the Elbe River, accepting the surrender of over 150,000 men of Lieutenant General Kurt von Tippelskirch's 21st Army on 2 May 1945. General Omar Bradley, commanding the US 12th Army Group, stated in a 1975 interview with Gavin that Field Marshal Sir Bernard Montgomery, commanding the Anglo-Canadian 21st Army Group, had told him that German opposition was too great to cross the Elbe. When Gavin's 82nd crossed the river, in company with the British 6th Airborne Division, the 82nd Airborne Division moved 36 miles in one day and captured over 100,000 troops, causing great laughter in Bradley's 12th Army Group headquarters.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.